Ceftaroline Fosamil

Infection caused by multidrug-resistant Gram-positive bacteria is a core challenge in current clinical anti-infective therapy. In particular, the prevalence of pathogenic bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP) has led to a continuously rising demand for the research and development of new antibacterial agents. Ceftaroline fosamil is a fifth-generation cephalosporin antibiotic, which inhibits cell wall synthesis by binding to bacterial penicillin-binding proteins (PBPs). Compared with traditional cephalosporins, it maintains potent activity against Gram-positive drug-resistant bacteria such as MRSA, while covering common Gram-negative bacteria. It is mainly used clinically to treat adult community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, providing a better first-line treatment option for patients with drug-resistant bacterial infections.

At present, the global market size of fifth-generation cephalosporins maintains steady growth, and the overall market size exceeded USD 1.2 billion in 2023. As the core variety of this category, ceftaroline fosamil maintains a compound annual growth rate of around 8%. The domestic market is still in the early stage of development, and only the originator product has been approved for marketing at present. With the improvement of the diagnosis and treatment rate of drug-resistant bacterial infections and the expansion of medical insurance coverage, it is expected that the domestic market size will exceed RMB 500 million in the next 3 years. In terms of the competitive landscape, no generic drug has been approved in China at present, and more than 3 enterprises have submitted marketing applications for generic drugs. The competition in the generic drug track will gradually heat up after the patent expires.

The originator enterprise of ceftaroline fosamil is Merck & Co., Inc., and the originator brand name is Teflaro. Its core compound patent in the United States expired in 2021, and the core patent in China will expire in 2024. The dosage form of the originator product for marketing is injection, with specifications of 0.5g and 2g. It has been included in the FDA Reference Listed Drug Catalog, and is also included in the *Catalog of Reference Preparations for Chemical Drugs* of China. In terms of domestic API registration, there is no domestic API registration number with A status at present. The originator preparation was approved by the National Medical Products Administration for import and marketing in 2021, and no domestic preparation has been approved yet. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for ceftaroline fosamil API, covering a full series of reference materials such as synthetic process intermediates and degradation impurities. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the demand for impurity reference materials in the process of generic drug research and development, quality research and production of pharmaceutical enterprises.